Partnering
In Almirall, we are committed to build value through partnering via:
- Actively pursuing new licensing opportunities in our territories.
- Selected company and product acquisitions.
- Finding suitable partners for our R&D projects.
- Co-operating with commercially well-established local partners in the countries where we do not have a direct presence.
What are our strengths and what do we offer?
- Commercial presence in Europe and Mexico:
- 11 affiliates in Europe (Austria, Belgium, France, Germany, Italy, Nordic countries, Poland, Portugal, Spain, Switzerland and United Kingdom & Ireland) and one in Latin America (Mexico).
- Experienced sales & marketing professionals.
- Proven R&D experience particularly devoted to respiratory, dermatology and autoimmune areas.
- Proprietary technology platform for developing inhaled products.
- Expertise in the management of regulatory procedures and clinical trials in the EU and USA.
- Excellent know-how and resources in the entire manufacturing process, from active ingredient to finished product.
- Cash flow for investment in business opportunities.
- Leading products in key areas open for discussion in other markets.
Events
-
From 15/11/2010 to 17/11/2010
Lugar: Munich, Germany
-
Bio-Europe 2009
From 02/11/2009 to 04/11/2009Sponsors
Lugar: Viena, Austria -
Gastro 2009
From 21/11/2009 to 25/11/2009Lugar: London, UK
-
Bio Business 2010
From 19/01/2010 to 20/01/2010Lugar: London, UK
-
Bio-Europe Spring 2010
From 08/03/2010 to 10/03/2010Lugar: Barcelona, Spain
-
BIO 2010
From 03/05/2010 to 06/05/2010Lugar: Chicago, USA
-
Euro-Biotech Forum 2010
From 28/06/2010 to 30/06/2010Lugar: Paris, France
Contact us
Would you like further information?
All fields are compulsoryNews on agreements
- Almirall announces an international agreement with Basilea to commercialize Toctino® (alitretinoin) for severe chronic hand eczema
- Almirall signs a pan-European licensing-in agreement with Ironwood for linaclotide, a novel gastrointestinal compound
- Almirall signs a co-marketing agreement with Recordati for the marketing of silodosin in Spain, a new compound for benign prostatic hyperplasia

















Optimized for Internet Explorer